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Abstract
It has been suggested that the evolution of vertebrate opioid receptors (ORs) follow a vector of 
increased functionality. Here we test this idea comparing human and frog ORs. Interestingly, some 
of the most potent opioid peptides known have been isolated from amphibian skin secretions. Here 
we show that such peptides (dermorphin and deltorphin) are highly potent in the human receptors 
and inactive in frog ORs. The molecular basis for the insensitivity of the frog ORs to these 
peptides was studied using chimeras and molecular modeling. Interestingly, the insensitivity of the 
delta opioid receptor (DOR) to deltorphin was due to variation of a single amino acid– Trp7.35—
which is a leucine in mammalian DORs. Notably, Trp7.35 is completely conserved in all known 
DOR sequences from lamprey, fish and amphibians. The deltorphin-insensitive phenotype was 
verified in fish. Our results provide a molecular explanation for the species selectivity of skin-
derived opioid peptides.
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Opioid receptors (ORs) mediate the analgesic and antinociceptive effects of endogenous 
opioid peptides and exogenous opioid small molecules in vertebrates [1–3]. The three classic 
opioid receptors, designated µ, δ and κ (MOR, DOR and KOR), were originally 
characterized by the pharmacological profiles of their responses to both shared and type-
specific ligands [1]. The genes for these three ORs, along with the related nociceptin 
receptor, occur on separate chromosomes in most known vertebrate genomes [1, 2]. 
Sequence-based studies of ORs have suggested that these four ORs arose via two genome-
wide pre-Mesozoic duplication events [2, 4–7].
Early studies of the analgesic and antinociceptive effects of opioid compounds in 
amphibians and fish provided evidence for the existence of opioid-like receptors in these 
organisms [3, 8–12], although these receptors differed pharmacologically from their 
mammalian orthologs. One of the first lines of evidence for this was derived from studies of 
KOR-like sites in the brain of the edible frog (Rana esculenta), in which it was reported that 
the KOR-like binding sites had higher affinities for MOR- and DOR-specific compounds 
than mammalian KOR receptors [13, 14]. Intriguingly, the degree of stereo-selectivity for 
arylacetamide and benzomorphan-derived ligands was also less at frog KOR than at the 
mammalian receptors [15].
All four opioid receptors have subsequently been cloned from additional amphibian and fish 
species [6, 16–23], and genome sequencing projects have revealed these same receptors in a 
large number of other species. The sequences of the four types of opioid receptors are highly 
conserved among species, with the most striking differences between the mammalian and 
non-mammalian receptors being in the extracellular loop domains [2, 6]—regions 
considered to constitute the “selectivity filter” of opioid receptors [24, 25]. In general, 
pharmacological studies have revealed that opioid receptors from mammals are more 
selective than those from non-mammals, [21–23, 26] leading to the hypothesis that opioid 
receptor type-selectivity exhibits an evolutionary vector of increased selectivity from fish 
and amphibians to mammals [2]. Among the many striking differences between the opioid 
systems of mammals and amphibians is the presence of highly potent endogenous opioid 
peptides (deltorphins [27] and dermorphins [28]) in the skin of many amphibians and 
mollusks [29]. Here we show that, although opioid-like peptides from amphibian epidermal 
secretions are remarkably potent at the human receptors, they do not activate the frog 
receptors. Further, by using human–frog chimeric receptors, site-directed mutagenesis and 
molecular modeling of newly-solved structures of opioid receptor-peptide complexes, we 
established the molecular basis of these differences. Our results predicted that DORs from 
Lamprey, Fish and Amphibian (LFA) sources would be insensitive to deltorphin, and we 
confirmed this prediction by showing that they are inactive in zebrafish in vivo.
Results
Pharmacological comparison of human and frog (Rana pipiens) opioid receptors
In preliminary experiments, we tested the expression levels of three human (hKOR, hMOR, 
hDOR) and three frog (Rana pipiens; rpKOR, rpMOR, rpDOR) opioid receptors via 
Vardy et al. Page 2













saturation binding assays using 3H-diprenorphine (see Methods for details). All transfected 
receptors displayed high affinity 3H-diprenorphine binding (KD’s ranged from 0.6 to 2.2 
nM), with high expression levels (βmax ranged from 2–8 pmol/mg) (Table 1), facilitating 
the comparison of functional data between species.
We used a previously described Gαi assay [30–34]to characterize the differential selectivity 
profiles of Rana pipiens versus human ORs (Table 2). For these studies, we evaluated the 
agonist potencies and efficacies of 14 agonists at each of the three different ORs from Rana 
pipiens and humans. In most cases when comparing human and frog ORs, agonists 
maintained their type selectivity albeit with lower potencies at the frog receptors. Thus, for 
example, the δ-selective ligand DADLE ([D-Ala2,D-Leu5]-enkephalin) was 90-fold less 
potent at the frog than at the human DOR. Similarly the μ-selective agonist DAMGO ([D-
Ala2,N-MePhe4,Gly-ol]-enkephalin) was 300-fold less potent at the frog than at the human 
MOR. Interestingly, the differences between frog and human receptors were less 
pronounced when naturally occurring mammalian opioid peptides were evaluated. Thus, for 
example, the endomorphins were 20-fold less potent at the frog MOR than at the human 
MOR. Interestingly, whereas all of the tested KOR-specific peptides (dynorphin A, 
dynorphin B and α-neoendorphin) were 10-fold less potent at the frog KOR, the amphibian 
dynorphin xendorphin [35, 36] was equally active at frog and human KORs. Type selectivity 
was mostly maintained in frog relative to human ORs. However, in the case of the synthetic 
peptides DADLE and DAMGO, type selectivity differed between species (see Table 2 for 
details). By contrast, the KOR-selective dynorphins, as well as the small molecule salvinorin 
A, were similarly selective in human and amphibian KORs.
The most pronounced differences between the human and frog receptors were seen with the 
dermorphin and deltorphin peptides, which are secreted in the skin of the tree frog-
Phyllomedusa bicolor. As previously documented, dermorphin is a potent and selective 
human MOR agonist, and deltorphin II and deltorphin C are potent and selective human 
DOR agonists. Deltorphin II and deltorphin C were inactive at the three tested frog ORs (Fig 
2B; Table 2) while dermorphin was an exceedingly weak agonist (Fig 2A; Table 2).
Identification of the molecular determinants of the pharmacological differences between 
frog and human opioid receptors
We next sought to determine the molecular basis for this striking species selectivity. An 
analysis of the sequences of human and frog receptors revealed that, for the most part, the 
major differences between these ORs reside in the extracellular loops and the receptor 
termini [6] (Fig. 1, Supp. Fig. 1). We hypothesized that the functional differences between 
human and frog ORs stem from differences in their corresponding sequences. Therefore, to 
characterize the molecular basis for the pharmacological differences between the frog and 
human MORs and DORs, a series of chimeric receptors was made to produce frog ORs with 
human “inserts” in various transmembrane and extracellular domains (Fig. 1B and 1C; 
Supplementary Table 2), covering most of the differences between the species, except for 
the N- and C- termini. The chimeras were designed to explore the idea that sequences in 
certain regions of the human receptors may be critical for their increased sensitivity 
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compared to their frog homologs. The new chimeras and mutants explored most of the 
differences between human and frog ORs, except for the N- and C- termini.
(a) Mu opioid receptors—Four chimeras (Fig. 1B–1 to 4) were made that swapped 
single stretches of human MOR sequences into the frog MOR. Functional analyses of the 
responses of these four chimeras to endomorphin, dermorphin or DAMGO showed that their 
responses were essentially identical to the wild-type frog MOR. Since the N-terminus of the 
human MOR had been implicated in the binding of opioid peptides [37], we constructed 3 
additional MOR chimeras (Fig. 1B-5 to 7) by “humanizing” the N termini of three 
constructs (residues 1 to 220 of WT rpMOR, rpMOR EL2h and rpMOR EL3h). These 
chimeras, h-rpMOR-WT, h-rpMOR-EL2h and h-rpMOR-EL3h were more responsive to the 
tested peptides than the WT rpMOR (Fig. 2A and Table 3). Moreover, the “humanization” 
of different regions had differential effects on the responses to various peptides – the activity 
of DAMGO, endomorphin 1 and 2 in rpMOR was partially rescued by humanization of the 
N-terminus, and even further enhanced by humanization of EL3h, but not by EL2h (Table 
3). Interestingly, the activity of dermorphin with the chimeric MOR followed a different 
pattern (Table 3 and Fig. 2A); humanization of the N-terminus rescued receptor activation 
by dermorphin, which was slightly enhanced by humanization of EL3 (~2-fold) and 
markedly enhanced by humanization of EL2 (~10-fold). We also examined the affinity of 
DAMGO and dermorphin to these chimeras using a competition binding assay with 
radiolabeled diprenorphine (Fig. 2A and Table 3). Interestingly, the affinity of DAMGO was 
not altered between the frog MOR and the three chimeras (Ki range 100–200 nM), whereas 
the affinity of dermorphin to rpMOR was increased by ~30-fold only in the h-rpMOR EL2h 
chimera, an effect that correlated well with the functional data.
(b) Delta opioid receptors—Five DOR chimeras (Fig. 1C-1 to 5), in which single 
stretches of the frog DOR were “humanized”, were constructed and tested by functional and 
binding studies with peptide ligands (Table S3 and Fig. 2B). Changing TM4 or TM5 from 
the frog sequence to the human sequence (Fig 1C–1 and 3) slightly reduced the activity of 
all four tested peptides, despite the fact that the human wild type receptor is more responsive 
to these ligands than the frog wild type receptor. Changing TM6 from frog to human (Fig. 
1C–4) slightly increased the potencies of all four peptides (Table S3). Changing EL2 from 
frog to human increased the potencies of DADLE, and the deltorphins, but not enkephalin 
(Table S3, Fig. 2B). Changing EL3 from frog to human increased the potencies and the 
affinities of all of the tested peptides.
To further explore the role of the EL3 region in DOR activity, we mutated several residues 
of interest in EL3 and the beginning of TM7 of rpDOR to their corresponding human 
residues. The mutants Met287Leu, Asn294Asp and Tyr296Leu maintained the rpDOR 
phenotype, i.e., they did not respond to deltorphin (data not shown), but the mutant 
Trp301Leu (7.35 in the numbering scheme of Ballesteros and Weinstein [38]) responded to 
deltorphin with substantially increased potency and affinity compared to rpDOR; this 
mutation also partially rescued activation by the other tested peptides (Table S3).
Structural basis of W 7.35 role in deltorphin selectivity—To evaluate the 
importance of position 7.35 in opioid receptors, we tested the effect of the reverse mutation 
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in the human DOR (Leu300Trp). Significantly, the L300W mutation diminished deltorphin 
potency nearly 2000-fold (Fig. 4). Bioinformatic analysis of DORs from multiple species 
reveals an interesting pattern – all of the known sequences of DOR from LFA (Lamprey, 
Fish and Amphibians) contain tryptophan at position 7.35 (Fig. 3A and B).
To elucidate a structural explanation for the role of W7.35 we next performed docking 
studies of deltorphins into the wild-type human DOR in complex with DIPP-NH2 
tetrapeptide (PDB – 4RWD) [39]and to a modeled L3.75W mutation. In this study, DIPP-
NH2 peptide has been found to have weak partial agonist activity at human (but not murine) 
DOR, though this entails only minor changes in the receptor binding pocket as compared 
antagonist naltrindole bound DOR. Therefore, the structure of DOR bound to a DIPP-NH2 
can provide information about the initial interaction between peptide agonists and the 
receptor. Both deltorphin C and deltorphin II are predicted to bind to the human DOR in 
similar binding poses, characterized by several key interactions with the receptor (Figure 
3D). Notably, the N-terminal amino group forms a salt bridge with the Asp128(3.32) side 
chain carboxylate group, while the tyrosine aromatic ring occupies a hydrophobic core 
pocket, with its hydroxyl group making polar interactions with ordered waters found in high 
resolution DOR structures. We note that inclusion of these water molecules in the structural 
model was important for consistently high-scoring docking of the peptide. Residues 1 to 4 of 
the ligand backbone adopt a well-defined turn conformation, which positions the D-Ala2 
and Phe3 side chains in hydrophobic subpockets, and allows the acidic side chain of Asp/
Glu4 to extend back into the pocket to form additional interactions with the N-terminal 
amino group and the Tyr56 side chain. Interestingly, free dynorphin peptides were predicted 
to preferentially adopt a very similar conformation for residues 1 to 4 in extensive energy 
optimizations. The C-terminal residues 5 to 7 are less defined in our docking, with several 
possible low energy conformations predicted for each peptide. Importantly, residue 7.35 is 
positioned at the entrance to the binding cavity and Leu7.35 in the human DOR comprises a 
part of the hydrophobic pocket that accommodates the benzene ring of the peptide Phe3 
[39]. In the frog DOR, however, mutation to a more bulky Trp7.35 side chain results in a 
prominent steric clash between its indole ring and Phe3. Attempts to dock deltorphins to the 
hDOR(Leu7.35Trp) mutant and a frog DOR model resulted in less consistent ligand poses 
and degraded binding scores. Taken together, these modeling results support a prominent 
role for residue 7.35 as a “selectivity filter” in DOR.
Zebrafish are insensitive to deltorphin—The mutagenesis and bioinformatic results 
suggested that the insensitivity of rpDOR to deltorphin was likely to be true of DORs from 
most, if not all, LFA. To test this prediction, an independent model system in which 
deltorphin affinity and potency had never been tested was selected; to that end, we tested the 
effect of DOR agonists on zebrafish swimming behavior. We treated larvae, 7 days post 
fertilization (dpf), with deltorphin or enkephalin peptides for 1 hour and quantified their 
swimming behavior (Fig. 5). When zebrafish were treated with either of the enkephalin 
peptides, we observed dose-dependent decreases in swimming levels. In contrast, the 
deltorphins had no significant effect on zebrafish swimming. We conclude that zebrafish are 
specifically sensitive to the enkephalin peptides and not deltorphins, likely due to the 
presence of W rather than L at position 7.35 of the zebrafish DOR.
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The main finding of this paper is that frog-derived opioid peptides show remarkable species-
selectivity which is specified –in the case of DOR—by a single amino acid change which 
has been conserved in all higher vertebrates. Clearly a functional comparison of orthologous 
receptors from different species can facilitate our understanding of the relationship between 
structure and function of these receptors; in addition, such comparisons may help us to 
understand how these receptors evolved, and the pressures that may have been exerted to 
promote such evolution. In the current study, we have verified that all of the frog and human 
receptors were functionally expressed in HEK293-T cells, and were coupled to Gαi, as 
would be predicted on the basis of sequence identity in the intracellular loop regions of 
opioid receptors from frogs and humans. We showed that, in most cases, human opioid 
receptors respond to both naturally occurring and synthetic peptides with higher potencies 
than opioid receptors from Rana pipiens. This is true in all of the examined cases except for 
the Xenopus laevis-derived peptide xendorphin, which demonstrated a comparable KOR-
specific activity in both human and frog KOR, and very low to no activity at MOR and DOR 
receptors. The KOR specificity of xendorphin has been previously demonstrated by 
displacement of a KOR radioligand from rat whole brain membranes [36].
The lower potencies observed for all of the frog ORs (Table 2) are consistent with previous 
reports characterizing other cloned non-mammalian ORs, including those from white 
suckerfish [16] and rough-skinned newt [21]. But in the case of the Xenopus dynorphin, 
xendorphin, we observed that, although frog receptors are not highly activated by 
mammalian peptides, the human receptors may be “compatible” with the amphibian 
peptides. Together, these data support the concept of an ‘evolutionary vector’ that leads 
from receptors with low responsiveness (low potency) in non-mammalian aquatic or 
amphibian vertebrates to those with high responsiveness and selectivity in mammals.
One of the initial motivations for this work was the observation that certain amphibians can 
secrete large quantities of extremely potent psychoactive compounds and peptides from their 
skin without apparent ill effects. It has been proposed that such secretions serve to protect 
against predators in nature [40, 41] and in other cases, it has been shown that the evolution 
of such natural defensive and survival strategies is often accompanied by resistance or 
insensitivity to certain natural materials [42–46]. As we show here, the amphibian opioid 
receptors we tested are insensitive to deltorphin and dermorphin and, in the case of 
deltorphin, this is due mainly to a difference in sequence at a single conserved residue—
leucine (mammalian) vs tryptophan (LFA) at position 7.35. Recent structural studies of 
antagonist-bound human MOR and DOR [30, 47, 48] show that residue 7.35 (Trp318 and 
Leu300, respectively) lies at the entrance to the binding site and is likely to be a part of the 
receptor specificity determinant [30, 47, 49, 50]. The Leu7.35Trp mutation in human DOR 
resulted in decreased affinity for some of the DOR-specific ligands [51], whereas mutations 
of the conserved tryptophan in MOR suggested the key role of this residue for MOR 
specificity [52, 53]. As opioid-like peptides from frog skin are thought to be a natural 
defense mechanism [40, 41], it would thus be advantageous for frogs that these peptides are 
inactive, although one would expect them to activate the receptors of potential frog 
predators.
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A comparison of the structures of human DOR and MOR [30, 47, 49, 50] revealed that there 
are 14 residues within 4 Å of the bound ligand, 11 of which are identical between the two 
receptors; the three differences are at positions (in MOR) Glu229 (in EL2), Lys303 (6.58) 
and Trp318 (7.35), which are Asp, Trp and Leu, respectively, in DOR. The substitution of 
leucine for tryptophan in DOR at position 7.35 is responsible for the binding selectivity both 
of the DOR-selective antagonist naltrindole and the conformationally constrained DOR-
selective peptide agonist [D-Pen2-D-Pen5]enkephalin (DPDPE) [51]. Additionally, the 
Trp318Leu (7.35) mutation increased the affinity of both of these ligands at MOR [54].
Our conformational modeling studies of the hDOR-deltorphin complexes also suggest that 
position 7.35 is the key position in the binding pocket that defines the difference in 
selectivity between human and frog receptors (Fig. 6). In the human DOR, both deltorphin C 
and deltorphin II are predicted to bind with their Phe3 side chain optimally positioned in a 
hydrophobic pocket formed by Leu300(7.35), Val281(6.55) and Trp284(6.58), making a π- 
stacking interaction with the latter. In the frog DOR, the Trp at position 7.35 narrows the 
binding pocket and results in a severe steric clash with Phe3 of the deltorphin peptide that 
precludes optimal ligand binding. Note that the conformation of the mutant Trp7.35 in frog 
DOR is stabilized by contacts with nearby residues, such as a stacking interaction with 
Trp6.58, precluding optimal adjustment of the pocket and hampering accommodation of 
deltorphins. Two other non-conserved residues of DOR, Val197 (Thr in frog) and Arg190 
(Lys in frog) in the ECL2 are in close proximity to the docked deltorphin and may interact 
with the ligand; however, such contacts in the more flexible and solvent-exposed part of the 
ligand are not predicted to significantly contribute to selectivity. This is in agreement with 
the observation that the Leu7.35Trp mutation in frog DOR almost completely rescues 
deltorphin binding, while the opposite mutation in the human receptor nearly eliminates 
deltorphin binding.
The molecular basis for the “species selectivity” of MOR-specific opioid like peptides from 
frog skin was also studied using chimeric receptors. The MOR-specific peptides tested in the 
current study were consistently more potent at the human than at the frog MOR. The 
sequences of the human and frog MORs differ in four regions, excluding the N- and C-
termini. In studies using chimeric receptors, there was little or no effect of replacement of 
regions of the frog MOR with the human sequence, unless the N-terminus of the frog MOR 
was also replaced by the human sequence (Fig. 1B 5–7). This was not surprising, since the 
N-termini of these two receptors differ markedly, and since the N-terminus of MOR has 
been shown to be critical for ligand binding [55]. Once the N-termini had been swapped, the 
results showed that the human EL3 was important for receptor activation by all of the 
studied peptides (Table 3), and that the human EL2 had only a small effect on activation, 
except for dermorphin (Table 3 and Fig. 2A). Thus EL2, along with the N-terminus, may be 
considered to be a ‘specificity determinant’ for dermorphin at MOR. The binding of 
DAMGO and dermorphin to the rpMOR chimeras was well correlated with the response of 
the chimeric receptors in the functional assays; however, there is a discrepancy between the 
binding and function of DAMGO and dermorphin in wild type rpMOR. DAMGO and 
dermorphin are at least 100-fold less potent in rpMOR than in any of the h-rpMOR 
chimeras, but both peptides bind to rpMOR with affinity that is only slightly lower than that 
of h-rpMOR-WT and h-rpMOR-EL3h (Fig. 2A). This phenomenon cannot be attributed to 
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low expression levels, since we have established comparable expression levels of human and 
frog receptors in HEK293 T cells (Table 1). It is conceivable that the N-terminus of MOR is 
involved in signaling or trafficking of the receptor, thus resulting in lower apparent receptor 
activity. The data presented here suggest that the low response of rpMOR to dermorphin and 
other peptides originates in the N-terminal region and in EL2.
The functional and binding data of the frog DOR and its humanized variants is more 
internally consistent than in the case of MOR, i.e., a lower potency is reflected in a lower 
binding affinity. In this case, we discovered that the EL3 of the frog DOR has an important 
role in its “deltorphin insensitive” phenotype. Further analysis led to the discovery that 
Trp301(7.35) of the frog DOR is the critical residue for insensitivity to deltorphin (Fig. 2B, 
Table 3). This notion was further supported by an analysis of the reverse mutation in the 
human receptor, Leu300Trp. The data in Figs. 2B and 3C demonstrate that Leu300 (7.35) is 
a critical residue for activation of hDOR by DOR-specific agonists, especially in the case of 
the Phyllomedusa-derived peptide deltorphin (Fig. 4). Phylogenetic analysis of DOR 
orthologs revealed that all of the available sequences from LFA contain a tryptophan at 
position 7.35 (Fig. 3A and B). Together, these data lead to the prediction that LFA are 
deltorphin-insensitive. This distinct functional difference between DORs from terrestrial 
vertebrates and non-mammalian aquatic vertebrates and amphibians (LFA) leads to a 
hypothesis that the increased sensitivity and selectivity of DOR have evolved, and been 
maintained, after divergence of amphibians and mammalians.
To test this “aquatic deltorphin insensitivity” hypothesis, we chose the zebrafish model 
system as an independent model; unlike enkephalins, deltorphins did not have any effect in 
the zebrafish swimming assay (Fig. 5). It is important to note that binding assays done with 
Rana pipiens tissue demonstrated that the affinities of deltorphin and dermorphin to ORs in 
the brains and spinal cord are very low, (30–80 μM) [56, 57] and, although these peptides 
have been suggested to have some in-vivo effects in Rana pipiens [58], it seems unlikely that 
these results are due to interactions with opioid receptors as they do not bind to them with a 
pharmacologically relevant affinity.
The skin secretions of frogs, toads and other amphibians contain a multitude of psychoactive 
compounds to which they may not be sensitive. Here this concept is demonstrated for opioid 
peptides, and it may be the case for other psychoactive alkaloids and peptides secreted by 
amphibians. The skin secretions of the toad Bufo alvarius contain, among other substances, 
the psychoactive compounds 5-Me-DMT and 5-OH-DMT; these compounds primarily 
target serotonin receptors, and they can generate different serotonin-like effects, including 
hallucinations [59]. Bombesin, bradykinin and tachykinin peptides are also found in the skin 
secretions of amphibians [41], and we hypothesize that the amphibian orthologs of the 
receptors for these compounds are likely to be insensitive to them. We are currently testing 
this hypothesis with a large number of other amphibian GPCR-skin secretants to determine 
if there is a generalized mechanism for this insensitivity related to differential receptor 
sensitivity.
It is interesting to consider the evolutionary advantages of these systems. Thus, for 
evolutionary success, the molecular structure of toxin target sites (e.g., receptors) should be 
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conserved in a phylogenetically wide spectrum of taxa [45]. Toxin inactivation or receptor 
insensitivity seems to be related to the development of such poisons. How ORs and opioid-
like peptides might have evolved in frogs remains a matter for speculation, although our data 
suggest that FLA maintained the deltorphin insensitive phenotype (Trp at position 7.35) 
even though there is no evidence that they secrete or come in contact with deltorphins in 
their natural habitats [60]. Phyllomedusa spp. (the source of the skin peptides) are 
considered by amphibian biologists the newest frog species [61, 62], suggesting that these 
peptides are a more recent evolutionary trait. Together these data suggest that the lower type 
selectivity hypothesized for opioid receptors in FLA, might have been important for the 
ability of later amphibian species to develop the highly potent opioid like peptides in their 
skin secretions.
Significance
Comparative pharmacology is useful for exploring questions related to structure function 
relationship and evolutionary mechanisms. Profound pharmacological distinctions along 
with a well-defined sequence differences between human and frog receptors allowed the 
identification of the molecular basis for an interesting evolutionary phenomena. It has been 
previously suggested that the evolution of vertebrate opioid receptors (ORs) followed a 
vector of increasing type selectivity and support this idea and show that as general rule 
opioid peptides activate human receptors to a higher degree than the frog receptors and the 
tested peptides exhibited increased type selectivity in the human receptors relative to the 
frog receptors. Interestingly, some of the most potent opioid peptides, known, have been 
isolated from amphibian skin secretions. Here we show that such peptides (dermorphin and 
deltorphin), while highly potent in the human receptors and inactive in frog ORs. The 
molecular basis for the insensitivity of the frog ORs to these peptides was studied using 
chimeras and molecular modeling. While the molecular mechanism for the insensitivity was 
not completely resolved due to its complexity, the delta opioid receptor (DOR) insensitivity 
to deltorphin was shown to be due to variation of a single amino acid– Trp7.35—which is a 
Leu in mammalian DORs. Notably, Trp7.35 is completely conserved in all known DOR 
sequences from lamprey, fish and amphibians. The deltorphin-insensitive phenotype was 
verified in zebra fish. Our results provide a molecular explanation for the species selectivity 
of skin-derived opioid peptides and raise an interesting discussion on the potential part that 
the low selectivity of frog ORs might have had in the development of such peptides.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection
Human embryonic kidney (HEK) 293T cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM; Corning) supplemented with 10% fetal bovine serum, 10 U/mL 
penicillin and 10 μg/mL streptomycin (Gibco). The cells were grown in a humidified 
incubator in the presence of 5% CO2 at 37 °C. Transient transfection (48 h) of wild-type, 
chimeric, and mutant receptor cDNAs was performed in 15-cm tissue culture plates using an 
optimized calcium phosphate method [63].
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Construction of Chimeric and Mutant Receptors
Human opioid receptor cDNAs in the mammalian expression vector pcDNA3.1(+) 
(Invitrogen) were obtained from the UMR cDNA Resource Center (www.cdna.org). Opioid 
receptors from Rana pipiens had previously been subcloned into the same vector [6]. Site-
directed mutagenesis was done using the QuikChange II® mutagenesis kit (Agilent) 
according to the manufacturer’s instructions, and all mutations were confirmed by full-
length automated DNA sequencing (Eton Bioscience, Durham, NC).
Generation of inter-species MOR and DOR chimeras was done using a two-step overlap 
PCR method, as previously described [64], and as diagrammed in Supplementary Fig. 2. The 
sequences of all primers used are given in Supplementary Table 1. A total of 5 DOR 
chimeras (Fig. 1C) and 7 MOR chimeras (Fig. 1B) was made by “humanizing” regions of 
the frog receptors (i.e., replacing stretches of residues from the frog receptors with their 
human counterparts).
In vitro characterization of OR activation
Radioligand Binding Assay—Radioligand binding assays were performed as previously 
detailed [65] using 3H-diprenorphine (Perkin Elmer) for saturation binding assays (10–0.1 
nM), with 10 μM unlabeled naltrexone (Sigma) to determine nonspecific binding.
Functional assay—Inhibition of cAMP production was measured using the genetically 
encoded cAMP biosensor, Glosensor-22F (Promega) as previously described [66].
Modeling of DOR-deltorphin interactions
Docking of opioid peptides was performed with the hDOR structure recently solved in 
complex with DIPP-NH2 peptide solved at 2.5 Å resolution (PDB: 4RWD) [39]. The 
receptor model was protonated and prepared using an ICM docking pipeline. Three models 
were tested, one with all 23 water molecules retained from the crystal structure, one without 
waters, and one with only the three water molecules mediating ligand interactions in hDOR-
DIPP-NH2 retained. These three waters were also found to be conserved among the 
structures of different opioid receptor types.
Fully flexible models of the heptapeptides deltorphin C (Tyr-D-Ala-Phe-Asp-Val-Val-Gly-
NH2) and deltorphin II (Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2) were docked into the hDOR 
model using the ICM energy-based docking algorithm, which takes advantage of the internal 
molecular coordinates of the ligand. A settings of thoroughness=30 was used to ensure 
exhaustive sampling of the peptide conformational space within the binding pocket. A large 
docking box (25×25×25 Å) was used to ensure that it completely covers the peptide binding 
pocket and the extracellular entrance of the receptor.
Ligand poses with the best binding scores were clustered and further analyzed using all atom 
optimization with side chain flexibility in the ligand binding pocket. Final energy-based 
binding scores were calculated using the ICM scoring algorithm. The mutation Leu7.35Trp 
was introduced by replacing the Leu7.35 side chain with the Trp side chain in ICM, 
followed by thorough energy-based optimization of the adjacent residues. The peptides were 
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docked in the mutated receptor, and binding scores calculated. In addition, the 
conformational preferences of the free deltorphin peptides in solvent were studied using 
exhaustive sampling of their rotamers, and the resulting low-energy conformations were 
compared to the docked deltorphins.
In vivo activity of DOR agonists in zebrafish
Aquaculture—We collected fertilized eggs from group matings of Ekkwill strain zebrafish 
(Ekkwill Waterlife Resources, Ruskin, FL). Embryos were raised in HEPES (10 mM, 
pH7.2) buffered E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2 and 0.33 mM 
MgSO4) on a normal 14/10 h on/off light cycle at 28 °C. At 3 days post-fertilization (dpf), 
chorion debris was removed and larvae were transferred into fresh medium until 7 dpf. At 7 
dpf, larvae were counted and manually pipetted, 10 larvae per well, into clear 96-well, U-
bottom plates (250μl/well) in the same medium.
Peptide treatment—All peptides were dissolved in DMSO, diluted to a 100X 
concentration and added directly to zebrafish medium in 96-well plates (2.5 μl in 250 μl). 
Wells were mixed and allowed to incubate for 1 h at 28 °C in ambient light prior to 
behavioral evaluation. The final DMSO concentration was 1%.
Swimming Assay—96-well plates were loaded into a ZebraBox containing a computer-
controlled light box and a video camera with an infrared filter (ViewPoint Life Sciences, 
Montreal, Quebec, Canada). Infrared light was used to illuminate the chamber and the 
temperature was maintained at 28 °C for the duration of the experiment. White light 
stimulation was automated using ZebraLab software (ViewPoint Life Sciences) as follows: 
dark for minutes 1, 3, 5 and 7; light for minutes 2, 4 and 6. At this age, darkness stimulates 
fish swimming [67]. Locomotor activity was recorded during the dark phases by the infrared 
camera using the ZebraLab Videotrack quantization mode at 30 frames/second. 96 evenly-
spaced regions of equal size were drawn around each well of the assay plate using the 
Viewpoint software. The software tracks the change in pixel intensity for each region over 
time producing a motion index, which correlates with the overall amount of motion in the 
well. Each video was saved for review and the data were further analyzed using custom R 
scripts. We used a Student’s t-test (2-tailed, unpaired, unequal variance) to analyze motion 
index values. An effect was considered significant if p<0.05. All zebrafish protocols were 
approved by the Institutional Animal Care and Use Committee at Massachusetts General 
Hospital.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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1. Comparison of frog and human opioid receptors show distinct pharmacology
2. Frog-derived opioid peptides secreted are potent in human but inactive in frogs
3. The molecular basis for δ-receptor species selectivity due to a single amino acid
4. The structural basis for this selectivity filter is elucidated
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Figure 1. Sequence divergence in ORs from frogs and humans
A- Crystal structures of the human KOR DOR and MOR. Transmembrane domains are 
colored using a color gradient from red (TM1) to blue (TM7), yellow regions are the 
receptor regions that differ between human and frog receptors (for more details, see 
sequence alignments in Fig. S1). B and C- Chimeras used in this study. rpDOR chimeras 
(B1–5) and rpMOR chimeras (C1–7). The chimeras were constructed by replacing regions 
of rpOR (white with grey outline) with their human corresponding sequences (black).
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Figure 2. Molecular basis for dermorphin and deltorphin insensitivity in rpORs
Inhibition of isoproterenol (300 nM) induced cAMP response and [3H]-diprenorphine 
competition in MOR variants by dermorphin and DAMGO (hMOR ●, rpMOR ■, h-rpMOR 
WT ▲, h-rpMOR – EL2h ▼, h-rpMOR – EL3h ◆) (A) and in DOR variants by deltorphin 
and DADLE (hDOR ■, rpDOR ●, rpDOR EL2h ●, rpDOR – EL2h ▲, rpDOR – EL3h ●) 
(B).
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Figure 3. Position 7.35 in DOR is the selectivity filter
A- comparison of DOR EL3-TM7 sequence from different species highlighting position 
7.35 with yellow (L) and green (W). B- Phylogenetic tree of vertebrate delta opioid 
receptors (full sequence) DOR from terrestrial vertebrates (yellow background) contains 
leucine at position 7.35 and DOR from non-terrestrial vertebrates (green background) 
contains tryptophan at position 7.35. C-The effect of tryptophan at position 7.35 in human 
DOR. Inhibition of cAMP response by three peptides in cells expressing hDOR or hDOR 
Leu300Trp. D-Zebrafish are sensitive to enkephalins but not deltorphins. Zebrafish larvae (7 
dpf) were treated with increasing concentrations of DOR peptide ligands for 1 h and then 
assayed for normal swimming activity. Results represent average motion ±SEM from 12 
replicate wells of 10 fish each, normalized to the vehicle (DMSO) control. Statistical 
analysis was performed using Student’s t-test (2-tailed, unpaired, unequal variance) 
significance was determined as follows: *p<0.05; **p<0.01.
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Figure 4. Structural model of Deltorphin and DOR
A- Surface representation of the binding pocket (cyan) of the delta opioid receptor and the 
docked position of Deltorphin C (orange). B and C –A Trp at position 7.35 of the hDOR 
Leu300Trp mutant protrudes into the binding pocket and narrows the entrance to the binding 
pocket. Deltorphin C (orange carbon atoms) and deltorphin II (yellow carbon atoms), 
docked into hDOR structure are shown in stick presentation. The Trp7.35 side chain in 
rpDOR (shown with magenta carbons in both stick and transparent sphere presentation) 
clashes with deltorphin peptides and can occlude their binding.
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